These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4678553)

  • 1. "Regulation of biological products".
    Fehnel PO
    Proc Inst Med Chic; 1972 Nov; 29(6):220. PubMed ID: 4678553
    [No Abstract]   [Full Text] [Related]  

  • 2. Allergenic extracts: a review of their safety and efficacy.
    Schaeffer M; Sisk LC
    Ann Allergy; 1984 Jan; 52(1):2-14. PubMed ID: 6364894
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of good manufacturing practice regulations to investigational biologic products.
    Goebel PW
    J Parenter Drug Assoc; 1980; 34(5):348-51. PubMed ID: 6905865
    [No Abstract]   [Full Text] [Related]  

  • 4. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new FDA combination products programme.
    Donawa M
    Med Device Technol; 2002 Oct; 13(8):25-8. PubMed ID: 12416330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making sure biologicals are safe.
    Hecht A
    FDA Consum; 1977; 11(6):21-6. PubMed ID: 10304996
    [No Abstract]   [Full Text] [Related]  

  • 8. Informed consent and living human cells.
    Maloney DM
    Hum Res Rep; 2002 Jul; 17(7):3. PubMed ID: 12731490
    [No Abstract]   [Full Text] [Related]  

  • 9. Introduction to the issues: appropriate methods of process validation.
    Scribner CL
    Dev Biol Stand; 1992; 76():213-4. PubMed ID: 1478338
    [No Abstract]   [Full Text] [Related]  

  • 10. The problem with the double-edged solution.
    Czap A
    Altern Med Rev; 2009 Jun; 14(2):96-8. PubMed ID: 19594219
    [No Abstract]   [Full Text] [Related]  

  • 11. CBER status on reform initiatives: industry reactions and comments.
    Page M
    Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilars legislation awakens data exclusivity debate.
    Hutson S
    Nat Med; 2009 Nov; 15(11):1242. PubMed ID: 19893548
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Institutional review boards and approval of new products without human subjects research.
    Maloney DM
    Hum Res Rep; 2002 Jul; 17(7):1-2. PubMed ID: 12731489
    [No Abstract]   [Full Text] [Related]  

  • 15. Biological products; blood specificity designators; technical amendments--FDA. Final rule; technical amendments.
    Fed Regist; 1994 May; 59(87):23636-7. PubMed ID: 10184096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 17. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 18. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
    Zoon KC
    Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
    [No Abstract]   [Full Text] [Related]  

  • 19. Introduction to the issues: viral vectors and potential problems in their use.
    Klinman DM
    Dev Biol Stand; 1992; 76():299-300. PubMed ID: 1478347
    [No Abstract]   [Full Text] [Related]  

  • 20. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability.
    Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.